Verbraeken H
Department of Ophthalmology, University Hospital Ghent, Belgium.
Graefes Arch Clin Exp Ophthalmol. 1996 May;234(5):288-93. doi: 10.1007/BF00220702.
Pars plana vitrectomy has both diagnostic and therapeutic potential in chronic uveitis. In this paper the therapeutic value of vitrectomy is investigated.
This is a retrospective study on 25 eyes that underwent pars plana vitrectomy with therapeutic intent. Surgery was considered in patients with severe vitreous clouding or macular pucker and in those who responded poorly or not at all to conventional treatment for uveitis. The mean period of follow up was 4.5 years, varying from 2 to 12 years.
Improved vision was observed in 56% of the eyes (14/25). Twenty-four percent of the eyes (6/25) had stable vision. Macular edema disappeared in 40% (10/25) of cases and persisted in 60% (15/25). Two of the nine eyes with persistent macular oedema progressed to a macular hole. Four of the six eyes with macular pucker suffered recurrence, one ended in phythisis, while the pucker was cured in only one patient. Twelve percent of the eyes (3/25) subsequently experienced a recrudescence of uveitis, making systemic treatment necessary. One patient presented, after vitrectomy, a traction retinal detachment with proliferating vitreoretinopathy. No complications or recurrences were seen in 44% of the eyes (11/25).
Vitrectomy has a definite place in the treatment of chronic uveitis, both on the functional level, with improvement or stabilisation of visual acuity and on the therapeutic level, with possible reduction or cessation of systemic treatment.
玻璃体切割术在慢性葡萄膜炎中具有诊断和治疗潜力。本文对玻璃体切割术的治疗价值进行了研究。
这是一项对25只接受治疗性玻璃体切割术的眼睛进行的回顾性研究。对于严重玻璃体混浊或黄斑皱襞的患者,以及对葡萄膜炎传统治疗反应不佳或无反应的患者,考虑进行手术。平均随访时间为4.5年,从2年到12年不等。
56%(14/25)的眼睛视力得到改善。24%(6/25)的眼睛视力稳定。40%(10/25)的病例黄斑水肿消失,60%(15/25)持续存在。9只持续性黄斑水肿的眼睛中有2只发展为黄斑裂孔。6只黄斑皱襞的眼睛中有4只复发,1只眼球萎缩,只有1例患者的皱襞得到治愈。12%(3/25)的眼睛随后葡萄膜炎复发,需要进行全身治疗。1例患者在玻璃体切割术后出现牵拉性视网膜脱离伴增殖性玻璃体视网膜病变。44%(11/25)的眼睛未出现并发症或复发。
玻璃体切割术在慢性葡萄膜炎的治疗中具有明确的地位,在功能层面上可改善或稳定视力,在治疗层面上可能减少或停止全身治疗。